These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

252 related articles for article (PubMed ID: 12008860)

  • 1. Hypericum perforatum versus fluoxetine in the treatment of mild to moderate depression.
    Behnke K; Jensen GS; Graubaum HJ; Gruenwald J
    Adv Ther; 2002; 19(1):43-52. PubMed ID: 12008860
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Double-blind, randomized trial of St John's wort, fluoxetine, and placebo in major depressive disorder.
    Fava M; Alpert J; Nierenberg AA; Mischoulon D; Otto MW; Zajecka J; Murck H; Rosenbaum JF
    J Clin Psychopharmacol; 2005 Oct; 25(5):441-7. PubMed ID: 16160619
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Equivalence of St John's wort extract (Ze 117) and fluoxetine: a randomized, controlled study in mild-moderate depression.
    Schrader E
    Int Clin Psychopharmacol; 2000 Mar; 15(2):61-8. PubMed ID: 10759336
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hypericum perforatum versus fluoxetine in the treatment of mild to moderate depression: a randomized double-blind trial in a Brazilian sample.
    Moreno RA; Teng CT; Almeida KM; Tavares Junior H
    Braz J Psychiatry; 2006 Mar; 28(1):29-32. PubMed ID: 16612487
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Differential therapy of mild to moderate depressive episodes (ICD-10 F 32.0; F 32.1) with St. John's wort.
    Friede M; Henneicke von Zepelin HH; Freudenstein J
    Pharmacopsychiatry; 2001 Jul; 34 Suppl 1():S38-41. PubMed ID: 11518073
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of an extract of hypericum (LI 160) and sertraline in the treatment of depression: a double-blind, randomized pilot study.
    Brenner R; Azbel V; Madhusoodanan S; Pawlowska M
    Clin Ther; 2000 Apr; 22(4):411-9. PubMed ID: 10823363
    [TBL] [Abstract][Full Text] [Related]  

  • 7. St. John's wort in mild to moderate depression: the relevance of hyperforin for the clinical efficacy.
    Laakmann G; Schüle C; Baghai T; Kieser M
    Pharmacopsychiatry; 1998 Jun; 31 Suppl 1():54-9. PubMed ID: 9684948
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical use of Hypericum perforatum (St John's wort) in depression: A meta-analysis.
    Ng QX; Venkatanarayanan N; Ho CY
    J Affect Disord; 2017 Mar; 210():211-221. PubMed ID: 28064110
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of St John's wort and imipramine for treating depression: randomised controlled trial.
    Woelk H
    BMJ; 2000 Sep; 321(7260):536-9. PubMed ID: 10968813
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Acute treatment of moderate to severe depression with hypericum extract WS 5570 (St John's wort): randomised controlled double blind non-inferiority trial versus paroxetine.
    Szegedi A; Kohnen R; Dienel A; Kieser M
    BMJ; 2005 Mar; 330(7490):503. PubMed ID: 15708844
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and tolerability of hypericum extract WS 5572 versus placebo in mildly to moderately depressed patients. A randomized double-blind multicenter clinical trial.
    Kalb R; Trautmann-Sponsel RD; Kieser M
    Pharmacopsychiatry; 2001 May; 34(3):96-103. PubMed ID: 11434406
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hypericum extract LI 160 and fluoxetine in mild to moderate depression: a randomized, placebo-controlled multi-center study in outpatients.
    Bjerkenstedt L; Edman GV; Alken RG; Mannel M
    Eur Arch Psychiatry Clin Neurosci; 2005 Feb; 255(1):40-7. PubMed ID: 15538592
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Superior efficacy of St John's wort extract WS 5570 compared to placebo in patients with major depression: a randomized, double-blind, placebo-controlled, multi-center trial [ISRCTN77277298].
    Kasper S; Anghelescu IG; Szegedi A; Dienel A; Kieser M
    BMC Med; 2006 Jun; 4():14. PubMed ID: 16796730
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and tolerability of Ze 117 St. John's wort extract in comparison with placebo, imipramine and fluoxetine for the treatment of mild to moderate depression according to ICD-10. An overview.
    Käufeler R; Meier B; Brattström A
    Pharmacopsychiatry; 2001 Jul; 34 Suppl 1():S49-50. PubMed ID: 11518076
    [No Abstract]   [Full Text] [Related]  

  • 15. [New developments in hypericum extracts: data on efficacy and interactions].
    Kraft K
    Wien Med Wochenschr; 2007; 157(13-14):284-7. PubMed ID: 17704973
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Do early changes in the HAM-D-17 anxiety/somatization factor items affect the treatment outcome among depressed outpatients? Comparison of two controlled trials of St John's wort (Hypericum perforatum) versus a SSRI.
    Bitran S; Farabaugh AH; Ameral VE; LaRocca RA; Clain AJ; Fava M; Mischoulon D
    Int Clin Psychopharmacol; 2011 Jul; 26(4):206-12. PubMed ID: 21278577
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Potential treatment for subthreshold and mild depression: a comparison of St. John's wort extracts and fluoxetine.
    Volz HP; Laux P
    Compr Psychiatry; 2000; 41(2 Suppl 1):133-7. PubMed ID: 10746915
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and tolerability of Hypericum perforatum in major depressive disorder in comparison with selective serotonin reuptake inhibitors: a meta-analysis.
    Rahimi R; Nikfar S; Abdollahi M
    Prog Neuropsychopharmacol Biol Psychiatry; 2009 Feb; 33(1):118-27. PubMed ID: 19028540
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effectiveness of St John's wort in major depression: a randomized controlled trial.
    Shelton RC; Keller MB; Gelenberg A; Dunner DL; Hirschfeld R; Thase ME; Russell J; Lydiard RB; Crits-Cristoph P; Gallop R; Todd L; Hellerstein D; Goodnick P; Keitner G; Stahl SM; Halbreich U
    JAMA; 2001 Apr; 285(15):1978-86. PubMed ID: 11308434
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The relationship between early changes in the HAMD-17 anxiety/somatization factor items and treatment outcome among depressed outpatients.
    Farabaugh A; Mischoulon D; Fava M; Wu SL; Mascarini A; Tossani E; Alpert JE
    Int Clin Psychopharmacol; 2005 Mar; 20(2):87-91. PubMed ID: 15729083
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.